<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23786" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Isoniazid</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>O'Connor</surname>
            <given-names>Courtney</given-names>
          </name>
          <aff>The University of Tennessee Health Science Center College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Brady</surname>
            <given-names>Mark F.</given-names>
          </name>
          <aff>Alpert Medical School of Brown University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Courtney O'Connor declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mark Brady declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>16</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23786.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Isoniazid (INH) is an antibiotic indicated in the first-line treatment of active&#x000a0;<italic toggle="yes">Mycobacterium tuberculosis</italic>&#x000a0;(TB) infection. INH has been&#x000a0;a significant drug in TB treatment regimens for decades. INH functions as a prodrug activated by the catalase-peroxidase KatG, generating various radicals and adducts that inhibit the production of mycolic acids, the essential components of the mycobacterium's cell wall. This mechanism of action makes INH a potent bactericidal agent. Moreover, INH exhibits synergistic effects with other species generated by KatG and other medications utilized in TB treatment.</p>
        <p>Mutations in the&#x000a0;<italic toggle="yes">katG</italic>, <italic toggle="yes">inhA</italic>, <italic toggle="yes">kasA</italic>, and <italic toggle="yes">ahpC</italic>&#x000a0;genes can lead to resistance against INH therapy. Resistance of <italic toggle="yes">M tuberculosis</italic> can occur more rapidly with INH monotherapy. This&#x000a0;activity reviews the indications, mechanism of action, and contraindications of INH as a valuable agent in treating both active and latent&#x000a0;TB infections. This activity also highlights the drug's adverse event profile, regimens and dosing, and other key factors pertinent to the interprofessional healthcare team when using&#x000a0;INH for TB treatment.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients with active or latent tuberculosis who can benefit from isoniazid (INH) treatment based on clinical guidelines and risk factors.</p></list-item><list-item><p>Screen patients for risk factors predisposing them to adverse reactions or interactions with isoniazid (INH), considering comorbidities and concomitant medications.</p></list-item><list-item><p>Apply knowledge of isoniazid's (INH's) mechanism of action and pharmacokinetics to optimize dosing and minimize the risk of resistance.</p></list-item><list-item><p>Collaborate with other healthcare professionals to coordinate comprehensive tuberculosis management, including monitoring for adverse effects, drug interactions, and treatment outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23786&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23786">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23786.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Isoniazid (INH) is an antibiotic indicated in the first-line treatment of active <italic toggle="yes">Mycobacterium tuberculosis</italic>&#x000a0;infection.</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>The US Food and Drug Administration (FDA) approved INH for the following indications:</p>
        <list list-type="bullet">
          <list-item>
            <p>Active tuberculosis&#x000a0;(TB) infection can present as fever, chills, night sweats, cough, hemoptysis, and weight loss. Four CDC-recommended multiple-drug regimens involve INH for drug-susceptible strains. The regimens consist of an initial phase of 2 months followed by a continuation phase of either 4 or 7 months.<xref ref-type="bibr" rid="article-23786.r1">[1]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Latent TB infection,&#x000a0;although rifampin-based regimens have recently replaced&#x000a0;INH as the primary recommendation. Rifampin-based regimens have demonstrated similar efficacy with a shorter treatment course and better completion rates.<xref ref-type="bibr" rid="article-23786.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with HIV infection with&#x000a0;purified protein derivative (PPD) tuberculin skin test &#x02265;5 mm induration and in patients with risk&#x000a0;factors for HIV infection with high suspicion of HIV infection.<xref ref-type="bibr" rid="article-23786.r3">[3]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Individuals with close contact with patients having TB and&#x000a0;PPD&#x000a0;&#x02265;5 mm.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Preventive therapy is&#x000a0;indicated with fibrotic pulmonary&#x000a0;lesions with recovered TB or in patients having pulmonary silicosis.<xref ref-type="bibr" rid="article-23786.r4">[4]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Intravenous (IV) drug users with PPD&#x000a0;&#x02265;10 mm.<xref ref-type="bibr" rid="article-23786.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Off-Label Use</bold>
</p>
        <p>According to the American Thoracic Society (ATS) and&#x000a0;the Infectious Diseases Society of America (IDSA),&#x000a0;INH is indicated for treating nontuberculous mycobacterial pulmonary disease.<xref ref-type="bibr" rid="article-23786.r6">[6]</xref></p>
      </sec>
      <sec id="article-23786.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Isoniazid&#x000a0;has been&#x000a0;a significant drug in TB treatment regimens since 1952. INH is a prodrug activated by the catalase-peroxidase KatG, creating a variety of radicals and adducts that inhibit the mycobacterium's production of the mycolic acids that make up its cell wall. This activity lends&#x000a0;INH the ability to be a potent bactericidal agent.&#x000a0;The drug also appears synergistic with other species produced by KatG and other medications used to treat TB.<xref ref-type="bibr" rid="article-23786.r7">[7]</xref>&#x000a0;However,&#x000a0;mutations in the&#x000a0;<italic toggle="yes">katG</italic>, <italic toggle="yes">inhA</italic>, <italic toggle="yes">kasA</italic>, and <italic toggle="yes">ahpC</italic>&#x000a0;genes may cause resistance&#x000a0;to INH therapy. <italic toggle="yes">M tuberculosis</italic>&#x000a0;resistance develops&#x000a0;more rapidly with&#x000a0;INH monotherapy.<xref ref-type="bibr" rid="article-23786.r8">[8]</xref><xref ref-type="bibr" rid="article-23786.r9">[9]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p><bold>Absorption:</bold> Rapid and complete absorption occurs after oral or intramuscular (IM) administration. The time of peak plasma concentration is 1 to 2 hours. INH is absorbed by the small intestine and is transported by the portal system to the liver.</p>
        <p><bold>Distribution:</bold> INH is rapidly distributed into all body tissue compartments, including cerebrospinal fluid. Plasma protein binding is&#x000a0;10% to 15%.&#x000a0;</p>
        <p><bold>Metabolism:&#x000a0;</bold>INH is inactivated via acetylation by <italic toggle="yes">N</italic>-acetyltransferase 2 (NAT2) in the liver and intestines.&#x000a0;Following the acetylation of INH, CYP2E1 oxidizes acetyl hydrazine into hepatotoxic metabolites. Rapid metabolizers can oxidize faster, which may increase the synthesis of hepatotoxins. Glutathione S-transferase (GST) protects against&#x000a0;hepatotoxins.&#x000a0;Combining GST with toxic metabolites forms&#x000a0;relatively non-toxic and water-soluble&#x000a0;metabolites that can be excreted easily.</p>
        <p><bold>Elimination:</bold> Most of the unchanged&#x000a0;drug (75% to 95%) and its metabolites are excreted in the urine, while small amounts are excreted in feces and saliva.<xref ref-type="bibr" rid="article-23786.r10">[10]</xref></p>
      </sec>
      <sec id="article-23786.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Available&#x000a0;INH formulations are&#x000a0;tablets (100 and 300 mg), syrup (50 mg/5 mL), or IV or IM injection (100 mg/mL).&#x000a0;In adults, 5&#x000a0;mg/kg up to 300 mg daily&#x000a0;as a single dose daily, or 15 mg/kg up to 900 mg/d in&#x000a0;2 to&#x000a0;3 divided doses per week is recommended, depending on the treatment regimen chosen. Clinicians should advise the patient not to take&#x000a0;INH with food as the bioavailability is decreased when administered with food.&#x000a0;</p>
        <p><bold>Active TB</bold>: According to the joint guidelines by the American Thoracic Society, Centers for Disease Control and Prevention (CDC), and Infectious Diseases Society of America, the preferred regimen for&#x000a0;active TB infections with drug-susceptible strains consists of&#x000a0;8 weeks of intensive&#x000a0;phase&#x000a0;treatment with INH, rifampin, pyrazinamide, and ethambutol (the RIPE regimens), followed by 18 weeks&#x000a0;continuation phase treatment with&#x000a0;INH and rifampin. Pyridoxine (vitamin B6), 25&#x000a0;to 50 mg/d, is administered with INH. The recommended dose of pyridoxine for patients with peripheral neuropathy is increased to 100 mg/d.<xref ref-type="bibr" rid="article-23786.r11">[11]</xref></p>
        <p><bold>Latent TB infection: </bold>Untreated latent&#x000a0;TB infection has approximately&#x000a0;a 5%&#x000a0;to 10%&#x000a0;risk of progression to TB during&#x000a0;the patient's lifetime. According to the guidelines by the CDC, for the treatment of latent TB infection, the preferred regimen is&#x000a0;3 months of&#x000a0;INH plus rifapentine, given weekly. An alternative regimen is&#x000a0;9 months of INH, given daily.<xref ref-type="bibr" rid="article-23786.r12">[12]</xref></p>
        <p>Dosing regimens for adults and children aged 12 and older: INH and rifapentine (RPT) &#x02013; given weekly for 3 months (12 doses).</p>
        <list list-type="bullet">
          <list-item>
            <p>INH 15 mg/kg rounded up to the nearest 50 or 100 mg; 900 mg maximum</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>RPT dosed 300 to 900 mg based on patient body weight</p>
          </list-item>
        </list>
        <p>INH and rifampin (RIF) &#x02013; dosed daily for 3 months (90 doses)</p>
        <list list-type="bullet">
          <list-item>
            <p>INH 5 mg/kg; 300 mg maximum</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>RIF&#x000a0;10 mg/kg; 600 mg&#x000a0;maximum</p>
          </list-item>
        </list>
        <p>INH monotherapy &#x02013; dosed for 6 or 9 months</p>
        <list list-type="bullet">
          <list-item>
            <p>6-month regimens:
<list list-type="bullet"><list-item><p>INH 5 mg/ kg daily; maximum dose 300 mg (180 doses)</p></list-item><list-item><p>INH 15 mg/kg twice weekly; maximum dose 900 mg (52 doses)</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>9-month regimens:
<list list-type="bullet"><list-item><p>INH 5 mg/kg daily; maximum dose 300 mg (270 doses)</p></list-item><list-item><p>INH 15 mg/kg&#x000a0;twice weekly; maximum dose 900 mg (76 doses)</p></list-item></list>
</p>
          </list-item>
        </list>
        <p><bold>Nontuberculous mycobacterial pulmonary disease: </bold>According to a joint guideline by ATS, IDSA, European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and European Respiratory Society (ERS),&#x000a0;patients with&#x000a0;<italic toggle="yes">M kansasii&#x000a0;</italic>infection&#x000a0;<italic toggle="yes">(</italic>rifampicin-susceptible&#x000a0;<italic toggle="yes">M kansasii)</italic>&#x000a0;should be treated with&#x000a0;daily administration of rifampicin, INH, and ethambutol. This regimen is associated with increased treatment success and lower relapse rates. Treatment should be continued for at least 12 months. The recommended dose of&#x000a0;INH is&#x000a0;5 mg/kg up to 300 mg daily.<xref ref-type="bibr" rid="article-23786.r6">[6]</xref></p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> The manufacturer's labeling&#x000a0;provides no dose adjustment guidance for patients with hepatic impairment. However,&#x000a0;INH is metabolized in the liver, so the drug should be used cautiously in these patients. Dose adjustment may be required&#x000a0;for acute or chronic liver disease patients to avoid adverse effects.<xref ref-type="bibr" rid="article-23786.r13">[13]</xref>&#x000a0;</p>
        <p><bold>Renal impairment: </bold>No dose adjustment is&#x000a0;needed for patients with&#x000a0;renal impairment. The recommendations are to administer a full dose of&#x000a0;INH in patients with impaired renal function despite prolonging the drug's half-life.<xref ref-type="bibr" rid="article-23786.r13">[13]</xref>&#x000a0;No supplement is required for patients on peritoneal or hemodialysis.</p>
        <p><bold>Pregnancy considerations:&#x000a0;</bold>INH is considered an FDA pregnancy category C medicine. INH may cross the placental barrier. Although&#x000a0;INH may not cause teratogenic effects, careful monitoring of pregnant patients is recommended. Using&#x000a0;INH therapy to treat active TB during pregnancy is recommended as the benefit outweighs the potential risk to the fetus. Pyridoxine supplementation is a recommended intervention for these patients.</p>
        <p>According to the CDC, the risk of untreated active TB disease in the pregnant woman and fetus is greater than the risks of treatment. Congenital TB can cause&#x000a0;bronchopneumonia and hepatosplenomegaly in neonates, with a high mortality rate. For drug-susceptible TB,&#x000a0;9 months of&#x000a0;treatment with INH, rifampin, and ethambutol should be given, considering the risk-benefit evaluation.<xref ref-type="bibr" rid="article-23786.r14">[14]</xref></p>
        <p><bold>Breastfeeding considerations:&#x000a0;</bold>The manufacturer recommends not discouraging breastfeeding as the small&#x000a0;amount of&#x000a0;INH in breast milk does not produce toxicity in the infant. Pyridoxine supplementation is recommended for these patients.<xref ref-type="bibr" rid="article-23786.r15">[15]</xref></p>
        <p><bold>Pediatric patients: </bold>According to the CDC and the National Tuberculosis Controllers Association, the preferred regimen for latent TB infection is&#x000a0;3 months of weekly&#x000a0;INH plus rifapentine&#x000a0;in children aged older than 2 years by directly observed therapy. The INH dose for children 2 to 11 years is 25 mg/kg/dose; for ages 12 and older, it is 15 mg/kg/dose. An alternative regimen is&#x000a0;9 months of daily INH (10 to 20 mg/kg).<xref ref-type="bibr" rid="article-23786.r12">[12]</xref>&#x000a0;For&#x000a0;active TB infection,&#x000a0;INH is always used with other antitubercular drugs; INH is&#x000a0;10&#x000a0;to 15 mg/kg daily or 20&#x000a0;to 30 mg/kg given twice weekly by directly observed therapy.<xref ref-type="bibr" rid="article-23786.r11">[11]</xref></p>
        <p><bold>Older patients: </bold>No&#x000a0;specific dose adjustment guidance is recommended in the manufacturer label for&#x000a0;older patients. Clinicians should exercise caution as the mortality from&#x000a0;TB&#x000a0;is&#x000a0;increased in&#x000a0;older patients.<xref ref-type="bibr" rid="article-23786.r16">[16]</xref></p>
      </sec>
      <sec id="article-23786.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Various adverse effects have been reported with&#x000a0;INH use; most are transient and low-grade.&#x000a0;Patients commonly experience gastrointestinal effects; some also report rash and pruritus. Peripheral neuropathy is also a commonly associated adverse event of&#x000a0;INH therapy, although its incidence is less than 0.2%. The risk may increase in patients with diabetes, HIV, nutritional deficiency, renal failure, alcoholism, and in women who are pregnant or breastfeeding. The mechanism of INH-induced peripheral neuropathy appears to involve interference of INH metabolites with vitamin B6 (pyridoxine) metabolism, resulting in decreased amounts of biologically active B6.&#x000a0;Thus, the treatment and prevention of peripheral neuropathy caused by&#x000a0;INH is pyridoxine supplementation during treatment.<xref ref-type="bibr" rid="article-23786.r1">[1]</xref><xref ref-type="bibr" rid="article-23786.r17">[17]</xref></p>
        <p>INH is also a CYP450 inhibitor (2C19: moderate,&#x000a0;3A4: weak), potentially resulting in elevated serum concentrations of concurrent drugs such as phenytoin, carbamazepine, diazepam, and primidone. Slow acetylation may be at a higher risk for these drug-drug interactions.<xref ref-type="bibr" rid="article-23786.r18">[18]</xref></p>
        <p>Drug-induced lupus erythematosus&#x000a0;(DILE) has been reported in up to&#x000a0;1% of patients taking INH. Half of the patients in these cases present with fever and pleuritis, and 30% with pericarditis.&#x000a0;Some experts think that slow acetylation poses an increased risk for the development of INH-induced lupus.<xref ref-type="bibr" rid="article-23786.r19">[19]</xref>&#x000a0;Anti-histone antibodies&#x000a0;are positive in most cases of drug-induced lupus.<xref ref-type="bibr" rid="article-23786.r20">[20]</xref>&#x000a0;Patients&#x000a0;on chronic hemodialysis are at increased risk of developing&#x000a0;severe encephalopathy.<xref ref-type="bibr" rid="article-23786.r21">[21]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>INH is a CYP450 inhibitor, potentially resulting in elevated serum concentrations of drugs such as diazepam and primidone. Slow acetylators may be at a higher risk for these drug-drug interactions.<xref ref-type="bibr" rid="article-23786.r18">[18]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>INH increases the plasma concentration of phenytoin. Therefore, to avoid phenytoin toxicity, phenytoin dose adjustment is advised.<xref ref-type="bibr" rid="article-23786.r22">[22]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Increased acetaminophen toxicity is reported with concurrent administration of INH. INH increases&#x000a0;the metabolism of acetaminophen, resulting in&#x000a0;a reduction of glutathione.&#x000a0;INH is also a potent inducer of CYP2E1, forming toxic metabolites and subsequent hepatotoxicity.<xref ref-type="bibr" rid="article-23786.r23">[23]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>INH inhibits the metabolism of carbamazepine, resulting in increased concentration and toxicity of carbamazepine. Therefore, the dose adjustment of carbamazepine is recommended.<xref ref-type="bibr" rid="article-23786.r16">[16]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Administration of&#x000a0;INH with theophylline may cause&#x000a0;increased plasma levels of theophylline. As theophylline has a narrow therapeutic index, therapeutic drug monitoring is recommended.<xref ref-type="bibr" rid="article-23786.r24">[24]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Intravesical bacillus Calmette&#x02013;Gu&#x000e9;rin (BCG) vaccination is contraindicated with concurrent use of INH.<xref ref-type="bibr" rid="article-23786.r25">[25]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23786.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>INH can be administered to patients with stable liver disease, although the risk for drug accumulation and drug-induced hepatitis may increase. These patients should receive more frequent monitoring.<xref ref-type="bibr" rid="article-23786.r1">[1]</xref> INH is contraindicated for patients with severe hypersensitivity reactions to&#x000a0;INH or other formulation components.<xref ref-type="bibr" rid="article-23786.r26">[26]</xref></p>
        <p>
<bold>Box Warning</bold>
</p>
        <p>Drug-induced liver injury (DILI) has been well documented with INH. INH-associated&#x000a0;hepatotoxicity&#x000a0;usually occurs during the first&#x000a0;3 months of treatment. Enzyme levels typically return to normal despite the continuation of the drug, but progressive liver&#x000a0;injury&#x000a0;has been reported. Risk factors associated with increased hepatotoxicity are&#x000a0;alcohol, preexisting chronic liver disease, IV drug abuse, and the postpartum period.<xref ref-type="bibr" rid="article-23786.r27">[27]</xref></p>
      </sec>
      <sec id="article-23786.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>In all adults preparing to begin INH treatment, the clinician should order baseline measurements of aspartate aminotransferase (AST), alanine aminotransferase (ALT), bilirubin, alkaline phosphatase, serum creatinine, and platelet count. Regular monitoring of hepatic and renal function during treatment is unnecessary unless the patient has abnormal baseline levels or is at increased risk for hepatotoxicity such as alcohol misuse and hepatitis B or C infection. Serum transaminases should be measured again&#x000a0;2 to&#x000a0;4 weeks after treatment initiation for those patients.<xref ref-type="bibr" rid="article-23786.r1">[1]</xref>&#x000a0;In patients with pulmonary TB, monthly sputum specimens are necessary (until 2 consecutive negative cultures) to assess response to treatment. Patients with poor compliance history should be&#x000a0;monitored with a urine test. Isoscreen test checks&#x000a0;for&#x000a0;INH metabolites in the urine.<xref ref-type="bibr" rid="article-23786.r28">[28]</xref><xref ref-type="bibr" rid="article-23786.r29">[29]</xref></p>
      </sec>
      <sec id="article-23786.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>The liver metabolizes INH primarily by acetylation with&#x000a0;<italic toggle="yes">N</italic>-acetyl transferase 2 (NAT2). Three metabolites have implications that correlate with the liver injury associated with the drug: acetyl hydrazine (AcHz), hydrazine (Hz), and a metabolite from the bioactivation of&#x000a0;INH itself. Considerable variation is apparent in the acetylation rate and elimination half-life from individual to individual, which is not accounted for by dose and concentration. This appears to contribute to the risk of hepatotoxicity and the other adverse effects associated with the drug.<xref ref-type="bibr" rid="article-23786.r30">[30]</xref></p>
        <p>Mild liver injury will occur in up to 20% of patients taking INH. Clinical manifestations of hepatotoxicity include fever, fatigue, nausea, and vomiting. However, most patients experiencing INH-induced liver injury are asymptomatic. Usually,&#x000a0;the condition is detected only by measuring increased levels of ALT and AST, which may rise to as high as&#x000a0;5 times the normal limit. In &#x0201c;adaptation,&#x0201d; the hepatic markers will return to normal in most patients with continued drug administration. About&#x000a0;1% of patients will experience severe liver injury;&#x000a0;INH therapy should&#x000a0;cease immediately. Reintroducing&#x000a0;INH in these cases is contraindicated as it can cause rapid symptom onset, and fatal hepatitis during&#x000a0;INH treatment is associated with continued use after symptoms of hepatitis are present.<xref ref-type="bibr" rid="article-23786.r31">[31]</xref>&#x000a0;</p>
        <p>INH-induced severe liver injury is generally associated with older patients and can be further exacerbated by concurrent treatment with rifampin, which induces CYP metabolism. Incidence is also higher in slow acetylators, which&#x000a0;correlates with higher serum levels of&#x000a0;INH and the AcHz metabolite. Additional risk factors include preexisting liver disease, a history of heavy alcohol use, and&#x000a0;patients in the postpartum period. More recently identified risk factors include polymorphisms in glutathione S-transferase, CYP2E1, TNF-&#x003b1;, and others.<xref ref-type="bibr" rid="article-23786.r30">[30]</xref>&#x000a0;Most patients recover entirely from&#x000a0;INH hepatotoxicity following drug discontinuation, although complete regression takes weeks.<xref ref-type="bibr" rid="article-23786.r32">[32]</xref></p>
        <p>INH doses above 30 mg/kg typically cause seizures, and doses exceeding 80 mg/kg can cause death. The most commonly reported adverse reactions to INH include seizures, coma, hyperthermia, and oliguria. Additionally, acute&#x000a0;INH toxicity is associated with excess lactic acid produced during episodes of intense muscular rigidity.</p>
        <p>Treating&#x000a0;INH overdose&#x000a0;requires establishing&#x000a0;a secure airway and prompt treatment for&#x000a0;hypotension and seizures. Pyridoxine helps to terminate seizures and should be administered in a 1:1 ratio of grams of&#x000a0;INH ingested. Pyridoxine should be supplemented with&#x000a0;IV benzodiazepines as pyridoxine and benzodiazepines display pharmacological synergism. INH has a low volume of distribution and low plasma protein binding; hemodialysis may be considered in refractory cases.<xref ref-type="bibr" rid="article-23786.r33">[33]</xref></p>
      </sec>
      <sec id="article-23786.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Clinicians&#x000a0;treating TB patients with INH must be aware of the patient's baseline liver function and the hepatotoxic risks associated with INH. Although estimates of fatal hepatitis associated with INH treatment are only 0.023%, these cases correlate with continued administration despite symptoms of hepatitis during treatment.<xref ref-type="bibr" rid="article-23786.r1">[1]</xref></p>
        <p>TB has widespread effects and greatly burdens individual patients and communities. Appropriate treatment is crucial for limiting the spread of TB and preventing drug resistance.&#x000a0;Therefore, a clinician treating TB&#x000a0;prescribes the appropriate treatment regimen and ensures adequate treatment adherence and completion.<xref ref-type="bibr" rid="article-23786.r1">[1]</xref>&#x000a0;A growing concern is INH-resistant strains of TB, and it appears that these may serve as precursors to multidrug-resistant strains.&#x000a0;Thus,&#x000a0;clinicians&#x000a0;should monitor patient progress to promptly detect patients not responding to INH treatment and who may harbor a resistant strain. INH-resistant strains require an altered regimen and increased efforts to prevent disease transmission.<xref ref-type="bibr" rid="article-23786.r34">[34]</xref><xref ref-type="bibr" rid="article-23786.r35">[35]</xref></p>
        <p>Public health departments typically provide TB treatment. They frequently collaborate as part of an interprofessional healthcare team with other entities such as private providers, community health centers, shelters, and others to ensure the completion of treatment. The interprofessional team should use a patient-centered approach&#x000a0;to tailor a treatment plan specific to each patient's needs to provide the best opportunity for treatment completion. This approach often involves social workers, case managers, and medical professionals; optimal communication and coordination of services are essential.&#x000a0;One way&#x000a0;for the team to maximize adherence is through direct observation of therapy (DOT), in which healthcare professionals provide the medications directly to the patient and watch as they swallow them. This approach has become the preferred method of drug administration for TB treatment. DOT allows for early identification of nonadherence, adverse effects, or worsening of a patient's condition.<xref ref-type="bibr" rid="article-23786.r1">[1]</xref>&#x000a0;</p>
        <p>Nurses and pharmacists&#x000a0;are also valuable members of this interprofessional approach by verifying doses, providing patient counsel, monitoring therapeutic progress, ensuring medication compliance, and monitoring adverse events. Nurses can use the&#x000a0;DOT method to ensure medication compliance. Consultation from obstetricians is necessary for TB in pregnancy. Pediatricians play an essential role in the overall management of TB in children.&#x000a0;Infectious disease consultation is&#x000a0;crucial&#x000a0;for multidrug-resistant TB and&#x000a0;nontuberculous mycobacterial pulmonary disease. Interprofessional coordination and collaboration&#x000a0;among&#x000a0;physicians, advanced practice practitioners,&#x000a0;specialists, pharmacists, nurses, and public health professionals&#x000a0;can enhance patient outcomes when using&#x000a0;INH therapy in treating TB&#x000a0;infection.</p>
      </sec>
      <sec id="article-23786.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23786&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23786">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23786/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23786">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23786.s11">
        <title>References</title>
        <ref id="article-23786.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blumberg</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Burman</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Chaisson</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Daley</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Etkind</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Friedman</surname>
                <given-names>LN</given-names>
              </name>
              <name>
                <surname>Fujiwara</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grzemska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hopewell</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Iseman</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Jasmer</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Koppaka</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>RI</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Reves</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Reichman</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Simone</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Starke</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Vernon</surname>
                <given-names>AA</given-names>
              </name>
              <collab>American Thoracic Society, Centers for Disease Control and Prevention and the Infectious Diseases Society</collab>
            </person-group>
            <article-title>American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2003</year>
            <month>Feb</month>
            <day>15</day>
            <volume>167</volume>
            <issue>4</issue>
            <fpage>603</fpage>
            <page-range>603-62</page-range>
            <pub-id pub-id-type="pmid">12588714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huaman</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sterling</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Latent Tuberculosis Infection-An Update.</article-title>
            <source>Clin Chest Med</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>4</issue>
            <fpage>839</fpage>
            <page-range>839-848</page-range>
            <pub-id pub-id-type="pmid">31731988</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ross</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Badje</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rangaka</surname>
                <given-names>MX</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Anglaret</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Eholie</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gabillard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Boulle</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maartens</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Golub</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Barnabas</surname>
                <given-names>RV</given-names>
              </name>
            </person-group>
            <article-title>Isoniazid preventive therapy plus antiretroviral therapy for the prevention of tuberculosis: a systematic review and meta-analysis of individual participant data.</article-title>
            <source>Lancet HIV</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>e8</fpage>
            <page-range>e8-e15</page-range>
            <pub-id pub-id-type="pmid">33387480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lanzafame</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vento</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Mini-review: Silico-tuberculosis.</article-title>
            <source>J Clin Tuberc Other Mycobact Dis</source>
            <year>2021</year>
            <month>May</month>
            <volume>23</volume>
            <fpage>100218</fpage>
            <pub-id pub-id-type="pmid">33598569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mamani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Majzoobi</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Torabian</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mihan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Alizadeh</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Latent and active tuberculosis: evaluation of injecting drug users.</article-title>
            <source>Iran Red Crescent Med J</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>15</volume>
            <issue>9</issue>
            <fpage>775</fpage>
            <page-range>775-9</page-range>
            <pub-id pub-id-type="pmid">24616784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Daley</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Iaccarino</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cambau</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Andrejak</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>B&#x000f6;ttger</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Brozek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Griffith</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Guglielmetti</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huitt</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Knight</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Leitman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marras</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Olivier</surname>
                <given-names>KN</given-names>
              </name>
              <name>
                <surname>Santin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Stout</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tortoli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>van Ingen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wagner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Winthrop</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.</article-title>
            <source>Clin Infect Dis</source>
            <year>2020</year>
            <month>Aug</month>
            <day>14</day>
            <volume>71</volume>
            <issue>4</issue>
            <fpage>e1</fpage>
            <page-range>e1-e36</page-range>
            <pub-id pub-id-type="pmid">32628747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chakraborty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>KY</given-names>
              </name>
            </person-group>
            <article-title>Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <year>2015</year>
            <month>Apr</month>
            <day>15</day>
            <volume>5</volume>
            <issue>8</issue>
            <fpage>a021147</fpage>
            <pub-id pub-id-type="pmid">25877396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghodousi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tagliani</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Karunaratne</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Niemann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Perera</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>K&#x000f6;ser</surname>
                <given-names>CU</given-names>
              </name>
              <name>
                <surname>Cirillo</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>Isoniazid Resistance in <italic>Mycobacterium tuberculosis</italic> Is a Heterogeneous Phenotype Composed of Overlapping MIC Distributions with Different Underlying Resistance Mechanisms.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2019</year>
            <month>Jul</month>
            <volume>63</volume>
            <issue>7</issue>
            <pub-id pub-id-type="pmid">31010866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>The impact of combined gene mutations in inhA and ahpC genes on high levels of isoniazid resistance amongst katG non-315 in multidrug-resistant tuberculosis isolates from China.</article-title>
            <source>Emerg Microbes Infect</source>
            <year>2018</year>
            <month>Nov</month>
            <day>16</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>183</fpage>
            <pub-id pub-id-type="pmid">30446638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erwin</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Addison</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>John</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>Olaleye</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Rosell</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of isoniazid: The good, the bad, and the alternatives.</article-title>
            <source>Tuberculosis (Edinb)</source>
            <year>2019</year>
            <month>May</month>
            <volume>116S</volume>
            <fpage>S66</fpage>
            <page-range>S66-S70</page-range>
            <pub-id pub-id-type="pmid">31076322</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nahid</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Dorman</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Alipanah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Barry</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Brozek</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Cattamanchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chaisson</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Chaisson</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Daley</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Grzemska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Higashi</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Hopewell</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Keshavjee</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Lienhardt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Merrifield</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Narita</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Peloquin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Raftery</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Saukkonen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schaaf</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Sotgiu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Starke</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Migliori</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Vernon</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>Oct</month>
            <day>01</day>
            <volume>63</volume>
            <issue>7</issue>
            <fpage>e147</fpage>
            <page-range>e147-e195</page-range>
            <pub-id pub-id-type="pmid">27516382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sterling</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Njie</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zenner</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Reves</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Menzies</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Horsburgh</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Crane</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Burgos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>LoBue</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Winston</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Belknap</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.</article-title>
            <source>MMWR Recomm Rep</source>
            <year>2020</year>
            <month>Feb</month>
            <day>14</day>
            <volume>69</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-11</page-range>
            <pub-id pub-id-type="pmid">32053584</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weber</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Hein</surname>
                <given-names>DW</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacokinetics of isoniazid.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>1979</year>
            <season>Nov-Dec</season>
            <volume>4</volume>
            <issue>6</issue>
            <fpage>401</fpage>
            <page-range>401-22</page-range>
            <pub-id pub-id-type="pmid">391461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miele</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bamrah Morris</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tepper</surname>
                <given-names>NK</given-names>
              </name>
            </person-group>
            <article-title>Tuberculosis in Pregnancy.</article-title>
            <source>Obstet Gynecol</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>135</volume>
            <issue>6</issue>
            <fpage>1444</fpage>
            <page-range>1444-1453</page-range>
            <pub-id pub-id-type="pmid">32459437</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <chapter-title>Isoniazid</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caraux-Paz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Diamantis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Wazi&#x000e8;res</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gallien</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Tuberculosis in the Elderly.</article-title>
            <source>J Clin Med</source>
            <year>2021</year>
            <month>Dec</month>
            <day>15</day>
            <volume>10</volume>
            <issue>24</issue>
            <pub-id pub-id-type="pmid">34945187</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stettner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Steinberger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hartmann</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Pabst</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Konta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hartung</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Kieseier</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>Isoniazid-induced polyneuropathy in a tuberculosis patient - implication for individual risk stratification with genotyping?</article-title>
            <source>Brain Behav</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>5</volume>
            <issue>8</issue>
            <fpage>e00326</fpage>
            <pub-id pub-id-type="pmid">26355945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Desta</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Soukhova</surname>
                <given-names>NV</given-names>
              </name>
              <name>
                <surname>Flockhart</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>45</volume>
            <issue>2</issue>
            <fpage>382</fpage>
            <page-range>382-92</page-range>
            <pub-id pub-id-type="pmid">11158730</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ankale</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sinha</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Iyer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jayalakshmi</surname>
                <given-names>TK</given-names>
              </name>
            </person-group>
            <article-title>Isoniazid Induced Lupus Presenting as Oral Mucosal Ulcers with Pancytopenia.</article-title>
            <source>J Clin Diagn Res</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>10</volume>
            <issue>10</issue>
            <fpage>OD03</fpage>
            <page-range>OD03-OD05</page-range>
            <pub-id pub-id-type="pmid">27891378</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>AYS</given-names>
              </name>
            </person-group>
            <article-title>Clinical use of anti-histone antibodies in idiopathic and drug-induced lupus.</article-title>
            <source>Immunol Med</source>
            <year>2022</year>
            <month>Dec</month>
            <volume>45</volume>
            <issue>4</issue>
            <fpage>180</fpage>
            <page-range>180-185</page-range>
            <pub-id pub-id-type="pmid">35383534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Constantinescu</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Buysschaert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Haufroid</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Broly</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Jadoul</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Morelle</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Chronic dialysis, NAT2 polymorphisms, and the risk of isoniazid-induced encephalopathy - case report and literature review.</article-title>
            <source>BMC Nephrol</source>
            <year>2017</year>
            <month>Sep</month>
            <day>04</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>282</fpage>
            <pub-id pub-id-type="pmid">28870161</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adithan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Subathra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>NAT2 gene polymorphism: covert drug interaction causing phenytoin toxicity.</article-title>
            <source>Indian J Med Res</source>
            <year>2016</year>
            <month>May</month>
            <volume>143</volume>
            <issue>5</issue>
            <fpage>542</fpage>
            <page-range>542-4</page-range>
            <pub-id pub-id-type="pmid">27487996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suzuki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Yuen</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Ilic</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Reese</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Ambroso</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Falls</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Comedications alter drug-induced liver injury reporting frequency: Data mining in the WHO VigiBase&#x02122;.</article-title>
            <source>Regul Toxicol Pharmacol</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>72</volume>
            <issue>3</issue>
            <fpage>481</fpage>
            <page-range>481-90</page-range>
            <pub-id pub-id-type="pmid">25988394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yew</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Clinically significant interactions with drugs used in the treatment of tuberculosis.</article-title>
            <source>Drug Saf</source>
            <year>2002</year>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>111</fpage>
            <page-range>111-33</page-range>
            <pub-id pub-id-type="pmid">11888353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Durek</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>R&#x000fc;sch-Gerdes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jocham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>B&#x000f6;hle</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Sensitivity of BCG to modern antibiotics.</article-title>
            <source>Eur Urol</source>
            <year>2000</year>
            <volume>37 Suppl 1</volume>
            <fpage>21</fpage>
            <page-range>21-5</page-range>
            <pub-id pub-id-type="pmid">10575268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Iwamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sutani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kuraki</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Isobe</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>[A case of atypical drug-induced hypersensitivity syndrome caused by isoniazid].</article-title>
            <source>Kekkaku</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>87</volume>
            <issue>12</issue>
            <fpage>777</fpage>
            <page-range>777-82</page-range>
            <pub-id pub-id-type="pmid">23350519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Denholm</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>McBryde</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Eisen</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Penington</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Street</surname>
                <given-names>AC</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of isoniazid preventative therapy for latent tuberculosis infection: a prospective cohort study.</article-title>
            <source>Drug Healthc Patient Saf</source>
            <year>2014</year>
            <volume>6</volume>
            <fpage>145</fpage>
            <page-range>145-9</page-range>
            <pub-id pub-id-type="pmid">25364275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soobratty</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Whitfield</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Subramaniam</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Grove</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Carver</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>O'Donovan</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>OY</given-names>
              </name>
              <name>
                <surname>Swaminathan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cope</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Milburn</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Point-of-care urine test for assessing adherence to isoniazid treatment for tuberculosis.</article-title>
            <source>Eur Respir J</source>
            <year>2014</year>
            <month>May</month>
            <volume>43</volume>
            <issue>5</issue>
            <fpage>1519</fpage>
            <page-range>1519-22</page-range>
            <pub-id pub-id-type="pmid">24435008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Subbaraman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Lubeck-Schricker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Khandewale</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thies</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Eliasziw</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Haberer</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Measuring Tuberculosis Medication Adherence: A Comparison of Multiple Approaches in Relation to Urine Isoniazid Metabolite Testing Within a Cohort Study in India.</article-title>
            <source>Open Forum Infect Dis</source>
            <year>2021</year>
            <month>Nov</month>
            <volume>8</volume>
            <issue>11</issue>
            <fpage>ofab532</fpage>
            <pub-id pub-id-type="pmid">35559123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Metushi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Uetrecht</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of isoniazid-induced hepatotoxicity: then and now.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>81</volume>
            <issue>6</issue>
            <fpage>1030</fpage>
            <page-range>1030-6</page-range>
            <pub-id pub-id-type="pmid">26773235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Ha</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>OJ</given-names>
              </name>
            </person-group>
            <article-title>Early monitoring for detection of antituberculous drug-induced hepatotoxicity.</article-title>
            <source>Korean J Intern Med</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>65</fpage>
            <page-range>65-72</page-range>
            <pub-id pub-id-type="pmid">26767859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saukkonen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Jasmer</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Schenker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jereb</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Nolan</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Peloquin</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Gordin</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Nunes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Strader</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Bernardo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Venkataramanan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sterling</surname>
                <given-names>TR</given-names>
              </name>
              <collab>ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee</collab>
            </person-group>
            <article-title>An official ATS statement: hepatotoxicity of antituberculosis therapy.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2006</year>
            <month>Oct</month>
            <day>15</day>
            <volume>174</volume>
            <issue>8</issue>
            <fpage>935</fpage>
            <page-range>935-52</page-range>
            <pub-id pub-id-type="pmid">17021358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glatstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carbell</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Scolnik</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rimon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Banerji</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hoyte</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Pyridoxine for the treatment of isoniazid-induced seizures in intentional ingestions: The experience of a national poison center.</article-title>
            <source>Am J Emerg Med</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>10</issue>
            <fpage>1775</fpage>
            <page-range>1775-1778</page-range>
            <pub-id pub-id-type="pmid">29397257</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stagg</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Lipman</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>McHugh</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>HE</given-names>
              </name>
            </person-group>
            <article-title>Isoniazid-resistant tuberculosis: a cause for concern?</article-title>
            <source>Int J Tuberc Lung Dis</source>
            <year>2017</year>
            <month>Feb</month>
            <day>01</day>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>129</fpage>
            <page-range>129-139</page-range>
            <pub-id pub-id-type="pmid">28234075</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23786.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sotgiu</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Centis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>D'ambrosio</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Migliori</surname>
                <given-names>GB</given-names>
              </name>
            </person-group>
            <article-title>Tuberculosis treatment and drug regimens.</article-title>
            <source>Cold Spring Harb Perspect Med</source>
            <year>2015</year>
            <month>Jan</month>
            <day>08</day>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>a017822</fpage>
            <pub-id pub-id-type="pmid">25573773</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
